| 000 | 01681 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513035811.0 | ||
| 264 | 0 | _c19951013 | |
| 008 | 199510s 0 0 eng d | ||
| 022 | _a0007-0920 | ||
| 024 | 7 |
_a10.1038/bjc.1995.414 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJanssen, R A | |
| 245 | 0 | 0 |
_aImmunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cSep 1995 |
||
| 300 |
_a795-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xmetabolism |
| 650 | 0 | 4 |
_aAntibodies, Bispecific _xmetabolism |
| 650 | 0 | 4 |
_aAntigens, Neoplasm _xpharmacology |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _ximmunology |
| 650 | 0 | 4 |
_aCell Adhesion Molecules _xpharmacology |
| 650 | 0 | 4 | _aEpithelial Cell Adhesion Molecule |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fragments _xmetabolism |
| 650 | 0 | 4 | _aImmunotherapy, Active |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 |
_aInterleukin-2 _xtherapeutic use |
| 650 | 0 | 4 |
_aKidney Neoplasms _ximmunology |
| 650 | 0 | 4 |
_aLeukopenia _xchemically induced |
| 650 | 0 | 4 |
_aLymphocyte Activation _xdrug effects |
| 650 | 0 | 4 |
_aT-Lymphocytes _ximmunology |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xmetabolism |
| 700 | 1 | _aKroesen, B J | |
| 700 | 1 | _aButer, J | |
| 700 | 1 | _aMesander, G | |
| 700 | 1 | _aSleijfer, D T | |
| 700 | 1 | _aThe, T H | |
| 700 | 1 | _aMulder, N H | |
| 700 | 1 | _ade Leij, L | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 72 _gno. 3 _gp. 795-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bjc.1995.414 _zAvailable from publisher's website |
| 999 |
_c7669029 _d7669029 |
||